Needham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsenNovember 8, 2021 5:36 AM Ionis Pharmaceuticals (IONS) PT Lowered to $33 at BarclaysNovember 4, 2021 4:56 AM Form 10-Q IONIS PHARMACEUTICALS For: Sep 30November 3, 2021 3:38 PM Form 8-K IONIS PHARMACEUTICALS For: Nov 03November 3, 2021 11:15 AM Ionis Pharmaceuticals (IONS) Misses Q3 EPS by 8cNovember 3, 2021 7:21 AM Ionis reports third quarter 2021 financial results and recent business achievementsNovember 3, 2021 7:00 AM